Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Cutan Pathol ; 48(5): 617-624, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33415780

RESUMO

BACKGROUND: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is associated with an increased risk of a second malignancy. METHODS: We conducted a retrospective clinicopathologic review of 12 patients with CLL/SLL who developed a second lymphoma in the skin. Demographic data, clinical information, and histopathology from 31 biopsies were recorded. Cases of secondary cutaneous involvement by CLL/SLL (leukemia cutis) and non-primary cutaneous lymphomas were excluded. RESULTS: A wide variety of primary cutaneous lymphomas was identified, including classic mycosis fungoides (3), cutaneous marginal zone lymphoma (2), primary cutaneous peripheral T-cell lymphoma unspecified (2), folliculotropic mycosis fungoides (1), Sézary syndrome (1), cutaneous gamma-delta T-cell lymphoma (1), cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (1), and cutaneous anaplastic large cell lymphoma (1). A male predominance was observed, and the average age was 74.1 years. In all patients, CLL/SLL predated the development of the second lymphoma, which was aggressive in the majority of cases (58%). Aggressive cytotoxic T-cell lymphomas, generally rare neoplasms, were relatively common (30%). CONCLUSIONS: CLL/SLL patients may develop a second lymphoma in the skin, which may be aggressive. Atypical cutaneous lymphoid infiltrates in this patient population should not be assumed to represent secondary CLL/SLL involvement and require thorough immunohistochemical analysis.


Assuntos
Leucemia Linfocítica Crônica de Células B/patologia , Linfoma/diagnóstico , Micose Fungoide/patologia , Neoplasias Cutâneas/patologia , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/análise , Biópsia , Feminino , Humanos , Leucemia Linfocítica Crônica de Células B/complicações , Linfoma de Zona Marginal Tipo Células B/complicações , Linfoma de Zona Marginal Tipo Células B/patologia , Linfoma Anaplásico de Células Grandes/complicações , Linfoma Anaplásico de Células Grandes/patologia , Linfoma Cutâneo de Células T/complicações , Linfoma Cutâneo de Células T/patologia , Masculino , Pessoa de Meia-Idade , Micose Fungoide/complicações , Segunda Neoplasia Primária/patologia , Estudos Retrospectivos , Síndrome de Sézary/complicações , Síndrome de Sézary/patologia , Neoplasias Cutâneas/metabolismo
2.
Mol Cancer Res ; 14(10): 1009-1018, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27418645

RESUMO

Recently, we identified that PREX1 overexpression is critical for metastatic but not tumorigenic growth in a mouse model of NRAS-driven melanoma. In addition, a PREX1 gene signature correlated with and was dependent on ERK MAPK activation in human melanoma cell lines. In the current study, the underlying mechanism of PREX1 overexpression in human melanoma was assessed. PREX1 protein levels were increased in melanoma tumor tissues and cell lines compared with benign nevi and normal melanocytes, respectively. Suppression of PREX1 by siRNA impaired invasion but not proliferation in vitro PREX1-dependent invasion was attributable to PREX1-mediated activation of the small GTPase RAC1 but not the related small GTPase CDC42. Pharmacologic inhibition of ERK signaling reduced PREX1 gene transcription and additionally regulated PREX1 protein stability. This ERK-dependent upregulation of PREX1 in melanoma, due to both increased gene transcription and protein stability, contrasts with the mechanisms identified in breast and prostate cancers, in which PREX1 overexpression was driven by gene amplification and HDAC-mediated gene transcription, respectively. Thus, although PREX1 expression is aberrantly upregulated and regulates RAC1 activity and invasion in these three different tumor types, the mechanisms of its upregulation are distinct and context dependent. IMPLICATIONS: This study identifies an ERK-dependent mechanism that drives PREX1 upregulation and subsequent RAC1-dependent invasion in BRAF- and NRAS-mutant melanoma. Mol Cancer Res; 14(10); 1009-18. ©2016 AACR.


Assuntos
GTP Fosfo-Hidrolases/genética , Fatores de Troca do Nucleotídeo Guanina/genética , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Melanoma/genética , Proteínas de Membrana/genética , Mutação , Proteínas Proto-Oncogênicas B-raf/genética , Animais , Linhagem Celular Tumoral , Movimento Celular , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Indazóis/farmacologia , Indóis/farmacologia , Sistema de Sinalização das MAP Quinases , Masculino , Melanoma/metabolismo , Camundongos , Piperazinas/farmacologia , Piridonas/farmacologia , Pirimidinonas/farmacologia , Sulfonamidas/farmacologia , Regulação para Cima , Vemurafenib
3.
Nat Commun ; 2: 555, 2011 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-22109529

RESUMO

Metastases are the major cause of death from melanoma, a skin cancer that has the fastest rising incidence of any malignancy in the Western world. Molecular pathways that drive melanoblast migration in development are believed to underpin the movement and ultimately the metastasis of melanoma. Here we show that mice lacking P-Rex1, a Rac-specific Rho GTPase guanine nucleotide exchange factor, have a melanoblast migration defect during development evidenced by a white belly. Moreover, these P-Rex1(-/-) mice are resistant to metastasis when crossed to a murine model of melanoma. Mechanistically, this is associated with P-Rex1 driving invasion in a Rac-dependent manner. P-Rex1 is elevated in the majority of human melanoma cell lines and tumour tissue. We conclude that P-Rex1 has an important role in melanoblast migration and cancer progression to metastasis in mice and humans.


Assuntos
Movimento Celular/fisiologia , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Melanoma/metabolismo , Melanoma/patologia , Metástase Neoplásica/fisiopatologia , Animais , Movimento Celular/genética , Células Cultivadas , Fatores de Troca do Nucleotídeo Guanina/genética , Humanos , Imuno-Histoquímica , Técnicas In Vitro , Melanoma/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Metástase Neoplásica/genética , Análise Serial de Tecidos
4.
Ophthalmic Plast Reconstr Surg ; 25(4): 330-2, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19617803

RESUMO

An 18-day-old child presented with rapid enlargement of a firm subcutaneous eyelid mass present since birth. Imaging revealed extension into the anterior orbit. Incisional biopsy revealed juvenile xanthogranuloma. Multidisciplinary systemic evaluation revealed no other lesions, although thrombocytopenia was discovered, prompting a bone marrow biopsy to rule out malignancy. Once none were uncovered, the thrombocytopenia was felt to be consistent with idiopathic thrombocytopenia. The patient was treated with intralesional steroid injections and concurrent oral prednisolone to normalize platelet count. The lesion softened, and reinjection 4 weeks later induced further regression, allowing the eyelid to clear the pupil. Although ocular involvement is a commonly reported extracutaneous manifestation of juvenile xanthogranuloma, a congenital subcutaneous eyelid lesion with orbital involvement has not been previously reported. Juvenile xanthogranuloma is typically benign and self-limiting; however, it can be associated with systemic disease, and treatment may be necessary to prevent amblyopia if the eyelid is involved. Early multidisciplinary evaluation for systemic lesions and associated malignant conditions should be considered.


Assuntos
Doenças Palpebrais/diagnóstico , Pálpebras/patologia , Xantogranuloma Juvenil/diagnóstico , Administração Oral , Biópsia , Dexametasona/administração & dosagem , Dexametasona/uso terapêutico , Diagnóstico Diferencial , Quimioterapia Combinada , Doenças Palpebrais/tratamento farmacológico , Seguimentos , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Humanos , Recém-Nascido , Injeções , Imageamento por Ressonância Magnética , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Triancinolona/administração & dosagem , Triancinolona/uso terapêutico , Xantogranuloma Juvenil/tratamento farmacológico
6.
Nat Neurosci ; 6(7): 717-23, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12796783

RESUMO

Agrin signals through the muscle-specific receptor tyrosine kinase (MuSK) to cluster acetylcholine receptors (AChRs) on the postsynaptic membrane of the neuromuscular junction (NMJ). This stands as the prevailing model of synapse induction by a presynaptic factor, yet the agrin-dependent MuSK signaling cascade is largely undefined. Abl1 (previously known as Abl) and the Abl1-related gene product Abl2 (previously known as Arg) define a family of tyrosine kinases that regulate actin structure and presynaptic axon guidance. Here we show that the Abl kinases are critical mediators of postsynaptic assembly downstream of agrin and MuSK. In mouse muscle, Abl kinases were localized to the postsynaptic membrane of the developing NMJ. In cultured myotubes, Abl kinase activity was required for agrin-induced AChR clustering and enhancement of MuSK tyrosine phosphorylation. Moreover, MuSK and Abl kinases effected reciprocal tyrosine phosphorylation and formed a complex after agrin engagement. Our findings suggest that Abl kinases provide the developing synapse with the kinase activity required for signal amplification and the intrinsic cytoskeletal regulatory capacity required for assembly and remodeling.


Assuntos
Proteínas Adaptadoras de Transdução de Sinal , Proteínas do Citoesqueleto , Proteínas de Homeodomínio/metabolismo , Junção Neuromuscular/fisiologia , Sinapses/fisiologia , Agrina/fisiologia , Animais , Animais Recém-Nascidos/crescimento & desenvolvimento , Animais Recém-Nascidos/metabolismo , Denervação Autônoma/métodos , Benzamidas , Western Blotting/métodos , Encéfalo/metabolismo , Bungarotoxinas/metabolismo , Agregação Celular/efeitos dos fármacos , Agregação Celular/fisiologia , Células Cultivadas , Relação Dose-Resposta a Droga , Interações Medicamentosas , Inibidores Enzimáticos/farmacologia , Proteínas de Homeodomínio/imunologia , Mesilato de Imatinib , Imuno-Histoquímica , Técnicas In Vitro , Camundongos , Denervação Muscular/métodos , Músculos/metabolismo , Mioblastos/metabolismo , Proteínas de Neurofilamentos/metabolismo , Fosforilação , Piperazinas/farmacologia , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-crk , Pirimidinas/farmacologia , Coelhos , Radioimunoensaio , Receptores Proteína Tirosina Quinases/metabolismo , Receptores Colinérgicos/metabolismo , Sinaptofisina/metabolismo , Fatores de Tempo , Transfecção/métodos , Tirosina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...